Akorn, Inc. is recalling 195,584 bottles of Rifampin capsules (150 mg and 300 mg) because tests revealed levels of an impurity called 1-Methyl-4-Nitrosopoperazine (MNP) that exceed safety limits. Rifampin is a prescription antibiotic used to treat tuberculosis and other infections. MNP is a type of nitrosamine, which is a substance that may increase the risk of cancer if a person is exposed to high levels over a long period of time. This recall affects various bottle sizes and lots distributed throughout the United States and Puerto Rico.
The product contains levels of the MNP impurity above the interim safety limit of 5 ppm. While this does not pose an immediate health threat, MNP is classified as a potential human carcinogen, and long-term exposure to levels above safety limits could potentially increase the risk of developing cancer.
You have 2 options:
Distributed by: Akorn Operating Company, LLC
Distributed by: Akorn Operating Company, LLC
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES ยท Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.